>Mercado de células madre pluripotentes inducidas (iPSC) de Asia Pacífico, por fuente celular (células de la piel y células sanguíneas), tipo (IPSC humanas e IPSC de ratón), producto (instrumentos, consumibles, kits y servicios), aplicaciones (investigación académica, medicina regenerativa, terapia celular, detección toxicológica, descubrimiento y desarrollo de fármacos, modelado de enfermedades, bancos de células madre, bioimpresión 3D y otros), usuario final (empresas biotecnológicas y farmacéuticas, laboratorios de investigación, laboratorios de diagnóstico y otros), canal de distribución (licitación directa y ventas minoristas), país (Japón, China, Corea del Sur, India, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas y resto de Asia Pacífico): tendencias de la industria y pronóstico hasta 2029.
Análisis y perspectivas del mercado: mercado de células madre pluripotentes inducidas (iPSC) en Asia y el Pacífico
Se espera que el mercado de células madre pluripotentes inducidas (iPSC) de Asia-Pacífico gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 12,2% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 460,45 millones para 2029. El aumento de las actividades de investigación sobre terapias con células madre actúa como impulsor del crecimiento del mercado de células madre pluripotentes inducidas (iPSC).
Las células madre pluripotentes inducidas son un tipo de células derivadas de los tejidos somáticos adultos y reprogramadas con un conjunto de genes y factores para obtener la naturaleza pluripotente. Se añaden ciertos genes y elementos para lograr propiedades definidas de las células madre embrionarias . Las células pluripotentes inducidas son casi idénticas a las células donantes, lo que ayuda en el modelado de enfermedades. Los retrovirus se utilizan comúnmente como vectores para reprogramar las células madre pluripotentes inducidas. Las principales aplicaciones de las células madre pluripotentes inducidas son el modelado de enfermedades, el descubrimiento y desarrollo de fármacos, los estudios de toxicidad y las terapias genéticas. Se utilizan ampliamente en tratamientos para enfermedades cardiovasculares , diabetes mellitus y varios tipos de cáncer. Las células madre pluripotentes inducidas humanas muestran las propiedades relevantes de la enfermedad, ya que llevan el genotipo específico de la enfermedad, lo que permite nuevas opciones terapéuticas de forma específica para el paciente.
La creciente adopción de terapias con células madre, el crecimiento del sector de la biotecnología con una mayor inversión y la creciente prevalencia de enfermedades crónicas actúan como impulsores del mercado de células madre pluripotentes inducidas (iPSC). Otros factores que se prevé que impulsen el crecimiento del mercado de células madre pluripotentes inducidas (iPSC) en Asia y el Pacífico incluyen la amplia gama de aplicaciones clínicas de las células madre pluripotentes inducidas y los avances tecnológicos emergentes de las iPSC.
However, the factors such as the high cost associated with stem cell therapies, availability of alternatives for tumor treatment are hampering the growth of the Asia-Pacific induced pluripotent stem cells (iPSCs) market. On the other hand, the rising number of pipeline products, increased interest of personalized medicine and surge in healthcare expenditure act as an opportunity for the growth of the Asia-Pacific induced pluripotent stem cells (iPSCs) market. The stringent rules and regulations and Genomic instability of IPSC is the key market challenge faced in the Asia-Pacific induced pluripotent stem cells (iPSCs) market.
The induced pluripotent stem cells (iPSCs) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the induced pluripotent stem cells (iPSCs) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size
The induced pluripotent stem cells (iPSCs) market is segmented on basis of cell source, type, product, applications, end users, and distribution channel The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Asia-Pacific induced pluripotent stem cells (iPSCs) market is categorized into six notable segments based on the cell source, type, product, applications, end users, and distribution channel.
- On the basis of cell source, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. In 2022, skin cells segment is expected to dominate the market due to easy availability of skin cells.
- On the basis of type, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. In 2022, human IPSCs segment is expected to dominate the market as they are majorly used for therapeutic applications
- On the basis of product, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables & kits and services. In 2022, consumables & kits segment is expected to dominate the market as they are used in toxicity testing and drug discoveries.
- On the basis of application, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modeling, stem cell banking, 3D bioprinting, and others. In 2022, drug discovery and development segment is expected to dominate the market as stem cells are gaining more attention novel drug inventions.
- On the basis of end-users, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into biotechnology & pharmaceutical companies, research laboratories, diagnostic laboratories, and others. In 2022, the biotechnology & pharmaceutical companies segment is expected to dominate the market due to high investment by companies to expand their facilities.
- On the basis of distribution channel, the Asia-Pacific induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. In 2022, direct tender segment is expected to dominate the market as they provide products with high quality.
Induced Pluripotent Stem Cells (iPSCs) Market Country Level Analysis
The induced pluripotent stem cells (iPSCs) market is analyzed, and market size information is provided by the country, cell source, type, product, applications, end users, and distribution channel as referenced above.
The countries covered in the induced pluripotent stem cells (iPSCs) market report are China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, and rest of Asia-Pacific.
Consumables & Kits segment in China of Asia Pacific region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of stem cell technology. The consumables & kits segment in Japan is second dominating the market owing to increasing cases of chronic diseases and high adoption of stem cell sources for better therapies. India is third in leading the growth of the Asia-Pacific market, and the consumables & kits segment is dominating in this country due to increasing number of biotechnology centers and research activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Induced Pluripotent Stem Cells (iPSCs) Treatment is Boosting the Market Growth of Induced Pluripotent Stem Cells (iPSCs) Market.
The induced pluripotent stem cells (iPSCs) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Induced Pluripotent Stem Cells (iPSCs) Market Share Analysis
Induced pluripotent stem cells (iPSCs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induced pluripotent stem cells (iPSCs) market.
The major companies which are dealing in the induced pluripotent stem cells (iPSCs) Thermo Fisher Scientific Inc., FUJIFILM Corporation, Hopstem Biotechnology LLC., Takara Bio Inc., Lonza., R & D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Merck KGaA and among others domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the induced pluripotent stem cells (iPSCs) market.
For instance,
- In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in Asia-Pacific market and leading to upsurge company’s growth in the coming years.
- In June 2020, the LumaCyte collaborated with Catalent who are the Asia-Pacific provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company’s stem cell technology product Radiance and its application.
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player is enhancing the company footprints in the veterinary infusion pumps market which also provides the benefit for organization’s profit growth.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CELL SOURCE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 ASIA PACIFIC MEDICAL CARTS MARKET: REGULATIONS
5.1 REGULATION IN U.S.
5.2 REGULATION IN CANADA
5.3 REGULATION IN EUROPE
5.4 REGULATION IN INDIA
5.5 REGUALTION IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT
6.2 RESTRAINT
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE
6.3.3 SURGE IN HEALTHCARE EXPENDITURE
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE
6.4.2 LACK OF SKILLED PROFESSIONALS
6.4.3 STRINGENT REGULATORY FRAMEWORK
7 IMPACT OF COVID-19 ON THE ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS BY MANUFACTURERS
7.5 CONCLUSION
8 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE
8.1 OVERVIEW
8.2 SKIN CELLS
8.2.1 FIBROBLAST
8.2.2 KERATINOCYTES
8.2.3 ADIPOSE DERIVED STEM CELLS
8.2.4 HEPATOCYTES
8.2.5 MELANOCYTES
8.2.6 NEURAL STEM CELLS
8.2.7 OTHERS
8.3 BLOOD CELLS
8.3.1 PERIPHERAL BLOOD
8.3.2 CORD BLOOD ENDOTHELIAL CELLS
8.3.3 CORD BLOOD STEM CELLS
8.3.4 OTHERS
9 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE
9.1 OVERVIEW
9.2 HUMAN IPSCS
9.3 MOUSE IPSCS
10 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 CONSUMABLES & KITS
10.2.1 REPROGRAMMING KITS
10.2.2 MEDIA
10.2.3 TRANSFECTION KITS
10.2.4 CELL IDENTIFICATION KITS
10.2.5 ACCESSORIES
10.2.6 OTHERS
10.3 SERVICES
10.4 INSTRUMENTS
10.4.1 IMAGING SYSTEMS
10.4.2 ELECTROPORATION DEVICE
10.4.3 INCUBATORS
10.4.4 OTHERS
11 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DRUG DISCOVERY AND DEVELOPMENT
11.3 ACADEMIC RESEARCH
11.4 DISEASE MODELLING
11.5 CELLULAR THERAPY
11.6 REGENERATIVE MEDICINE
11.7 TOXICOLOGY SCREENING
11.8 STEM CELL BANKING
11.9 3D BIOPRINTING
11.1 OTHERS
12 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER
12.1 OVERVIEW
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
12.3 RESEARCH LABORATORIES
12.4 DIAGNOSTIC LABORATORIES
12.5 OTHERS
13 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 THAILAND
14.1.8 MALAYSIA
14.1.9 INDONESIA
14.1.10 PHILIPPINES
14.1.11 REST OF ASIA-PACIFIC
15 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 FUJIFILM CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.1.5.1 ACQUISITION
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.2.5.1 EVENT
17.2.5.2 ACQUISITION
17.3 LONZA.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.3.5.1 EXPANSION
17.4 MERCK KGAA
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.4.5.1 AGREEMENT
17.5 EVOTEC SE.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.5.1 AGREEMENT
17.5.5.2 COLLABORATION
17.6 APPLIED STEMCELL.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.6.3.1 PRODUCT LAUNCH
17.7 AXOL BIOSCIENCE LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.7.3.1 MERGER
17.7.3.2 PRODUCT LAUNCH
17.8 CELL APPLICATIONS, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.8.3.1 PARTNERSHIP
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.9.4.1 ACQUISITION
17.1 CITIUS PHARMACEUTICALS, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.10.3.1 AGREEMENT
17.11 CORNING INCORPORATED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.11.4.1 AGREEMENT
17.12 FATE THERAPEUTICS
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 CLINICAL TRIAL
17.13 GENECOPOEIA, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 HOPSTEM BIOTECHNOLOGY LLC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PARTNERSHIP
17.15 HORIZON DISCOVERY LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 LUMACYTE
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.16.3.1 COLLABORATION
17.17 R & D SYSTEMS, INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 REPROCELL INC.
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.18.3.1 COLLABORATION
17.18.3.2 FACILITY EXPANSION
17.18.3.3 SERVICE LAUNCH
17.19 TAKARA BIO INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.19.4.1 NEW FACILITY LAUNCH
17.2 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.20.4.1 ACQUISITION
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tablas
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC HUMAN IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC MOUSE IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC SERVICES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC DRUG DISCOVERY AND DEVELOPMENT IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC ACADEMIC RESEARCH IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC DISEASE MODELLING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC CELLULAR THERAPY IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC REGENERATIVE MEDICINE IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC TOXICOLOGY SCREENING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC STEM CELL BANKING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC 3D BIOPRINTING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC RESEARCH LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC DIAGNOSTIC LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC DIRECT TENDER IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC RETAIL SALES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 46 CHINA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 47 CHINA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 48 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 50 CHINA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 CHINA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 56 JAPAN SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 57 JAPAN BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 58 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 JAPAN INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 61 JAPAN CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 62 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 66 INDIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 67 INDIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 68 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 70 INDIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 INDIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 75 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 76 SOUTH KOREA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 77 SOUTH KOREA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 78 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 81 SOUTH KOREA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 86 AUSTRALIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 87 AUSTRALIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 88 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 90 AUSTRALIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 91 AUSTRALIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 92 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 93 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 96 SINGAPORE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 97 SINGAPORE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 98 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 100 SINGAPORE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 101 SINGAPORE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 102 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 105 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 106 THAILAND SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 107 THAILAND BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 108 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 110 THAILAND INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 111 THAILAND CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 112 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 115 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 116 MALAYSIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 117 MALAYSIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 118 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 120 MALAYSIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 MALAYSIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 122 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 123 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 126 INDONESIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 127 INDONESIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 128 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 130 INDONESIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 131 INDONESIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 132 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 136 PHILIPPINES SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 137 PHILIPPINES BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 138 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 140 PHILIPPINES INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 141 PHILIPPINES CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 142 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 143 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 144 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 145 REST OF ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 11 THE WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS (IPSC) ARE EXPECTED TO DRIVE THE ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SKIN CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
FIGURE 15 PREVALENCE OF CHRONIC DISEASES
FIGURE 16 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
FIGURE 17 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2021
FIGURE 18 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2020-2029 (USD MILLION)
FIGURE 19 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, CAGR (2022-2029)
FIGURE 20 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, LIFELINE CURVE
FIGURE 21 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2021
FIGURE 22 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 23 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2021
FIGURE 26 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 27 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 28 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2021
FIGURE 30 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 31 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 32 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2021
FIGURE 34 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 35 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 36 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 38 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 39 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 40 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 42 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 43 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 44 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 45 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 46 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
